Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VENGEANCE: Trebananib + Bevacizumab in mCRC
NCT01249521Phase 2Unknown
- Sponsor
- Austin Health
- Start
- Nov 2010
- Primary completion
- Nov 2011
- Modality
- Peptides, Antibody-Based Therapeutics, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trebananib in metastatic colorectal cancer (mCRC), sponsored by Austin Health. Primary endpoint: Disease control (non-progression) at 6 months. Status: unknown.
02
Drugs
trebananib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01249521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01249521.